128 related articles for article (PubMed ID: 29473265)
1. Cytotoxic T lymphocyte response to peptide vaccination predicts survival in stage III colorectal cancer.
Kawamura J; Sugiura F; Sukegawa Y; Yoshioka Y; Hida JI; Hazama S; Okuno K
Cancer Sci; 2018 May; 109(5):1545-1551. PubMed ID: 29473265
[TBL] [Abstract][Full Text] [Related]
2. IgG response to MHC class I epitope peptides is a quantitative predictive biomarker in the early course of treatment of colorectal cancer using therapeutic peptides.
Kanekiyo S; Hazama S; Takenouchi H; Nakajima M; Shindo Y; Matsui H; Tokumitsu Y; Tomochika S; Tsunedomi R; Tokuhisa Y; Iida M; Sakamoto K; Suzuki N; Takeda S; Yamamoto S; Yoshino S; Okuno K; Udaka K; Kawakami Y; Matsueda S; Ito K; Nagano H
Oncol Rep; 2018 May; 39(5):2385-2392. PubMed ID: 29498403
[TBL] [Abstract][Full Text] [Related]
3. Multicenter, phase II clinical trial of peptide vaccination with oral chemotherapy following curative resection for stage III colorectal cancer.
Kawamura J; Sugiura F; Sukegawa Y; Yoshioka Y; Hida JI; Hazama S; Okuno K
Oncol Lett; 2018 Apr; 15(4):4241-4247. PubMed ID: 29541190
[TBL] [Abstract][Full Text] [Related]
4. [Treatment outcome of peptide vaccination for advanced colorectal cancer].
Sugiura F; Inoue K; Kogita A; Yoshioka Y; Hida J; Okuno K; Sukegawa Y
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1584-6. PubMed ID: 24393856
[TBL] [Abstract][Full Text] [Related]
5. [Clinical study of Peptide-cocktail vaccination with tegafur-uracil/leucovorin for advanced colorectal cancer].
Sugiura F; Inoue K; Okuno K; Sukegawa Y
Gan To Kagaku Ryoho; 2012 Nov; 39(12):1760-2. PubMed ID: 23267878
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 study of OCV-C02, a peptide vaccine consisting of two peptide epitopes for refractory metastatic colorectal cancer.
Taniguchi H; Iwasa S; Yamazaki K; Yoshino T; Kiryu C; Naka Y; Liew EL; Sakata Y
Cancer Sci; 2017 May; 108(5):1013-1021. PubMed ID: 28266765
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer.
Matsushita N; Aruga A; Inoue Y; Kotera Y; Takeda K; Yamamoto M
Oncol Rep; 2013 Mar; 29(3):951-9. PubMed ID: 23314271
[TBL] [Abstract][Full Text] [Related]
8. [Preliminary study of Peptide vaccine with UFT/LV as adjuvant setting for stage III colorectal cancer].
Okuno K; Sugiura F; Hida J; Tokoro T; Ishimaru E; Ueda K
Gan To Kagaku Ryoho; 2011 Nov; 38(12):1906-8. PubMed ID: 22202234
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer.
Okuno K; Sugiura F; Hida JI; Tokoro T; Ishimaru E; Sukegawa Y; Ueda K
Exp Ther Med; 2011 Jan; 2(1):73-79. PubMed ID: 22977472
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy with cancer peptides in combination with intravesical bacillus Calmette-Guerin for patients with non-muscle invasive bladder cancer.
Obara W; Hara I; Kato Y; Kato R; Inoue K; Sato F; Mimata H; Nakamura Y; Fujioka T
Cancer Immunol Immunother; 2018 Sep; 67(9):1371-1380. PubMed ID: 29971464
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome.
Hazama S; Nakamura Y; Takenouchi H; Suzuki N; Tsunedomi R; Inoue Y; Tokuhisa Y; Iizuka N; Yoshino S; Takeda K; Shinozaki H; Kamiya A; Furukawa H; Oka M
J Transl Med; 2014 Mar; 12():63. PubMed ID: 24612787
[TBL] [Abstract][Full Text] [Related]
12. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study.
Suzuki N; Hazama S; Iguchi H; Uesugi K; Tanaka H; Hirakawa K; Aruga A; Hatori T; Ishizaki H; Umeda Y; Fujiwara T; Ikemoto T; Shimada M; Yoshimatsu K; Shimizu R; Hayashi H; Sakata K; Takenouchi H; Matsui H; Shindo Y; Iida M; Koki Y; Arima H; Furukawa H; Ueno T; Yoshino S; Nakamura Y; Oka M; Nagano H
Cancer Sci; 2017 Jan; 108(1):73-80. PubMed ID: 27783849
[TBL] [Abstract][Full Text] [Related]
13. Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial.
Shimizu Y; Yoshikawa T; Kojima T; Shoda K; Nosaka K; Mizuno S; Wada S; Fujimoto Y; Sasada T; Kohashi K; Bando H; Endo I; Nakatsura T
Cancer Sci; 2019 Oct; 110(10):3049-3060. PubMed ID: 31390678
[TBL] [Abstract][Full Text] [Related]
14. Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients.
Hattori T; Mine T; Komatsu N; Yamada A; Itoh K; Shiozaki H; Okuno K
Cancer Immunol Immunother; 2009 Nov; 58(11):1843-52. PubMed ID: 19396597
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer.
Masuzawa T; Fujiwara Y; Okada K; Nakamura A; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Osawa R; Takeda K; Yoshida K; Tsunoda T; Nakamura Y; Mori M; Doki Y
Int J Oncol; 2012 Oct; 41(4):1297-304. PubMed ID: 22842485
[TBL] [Abstract][Full Text] [Related]
16. A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer.
Sundar R; Rha SY; Yamaue H; Katsuda M; Kono K; Kim HS; Kim C; Mimura K; Kua LF; Yong WP
BMC Cancer; 2018 Mar; 18(1):332. PubMed ID: 29587677
[TBL] [Abstract][Full Text] [Related]
17. Significant clinical response of advanced colon cancer to peptide vaccine therapy: a case report.
Yasuda S; Tsuchiya I; Okada K; Tanaka A; Suzuki T; Sadahiro S; Takeda K; Yamamoto S; Nakui M
Tokai J Exp Clin Med; 2012 Jul; 37(2):57-61. PubMed ID: 22763829
[TBL] [Abstract][Full Text] [Related]
18. Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients.
Kameshima H; Tsuruma T; Torigoe T; Takahashi A; Hirohashi Y; Tamura Y; Tsukahara T; Ichimiya S; Kanaseki T; Iwayama Y; Sato N; Hirata K
Cancer Sci; 2011 Jun; 102(6):1181-7. PubMed ID: 21371173
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel MAGE-A6- and MAGE-A12-derived HLA-A24-restricted cytotoxic T lymphocyte epitopes using an in silico peptide-docking assay.
Akiyama Y; Komiyama M; Nakamura Y; Iizuka A; Oshita C; Kume A; Nogami M; Miyata H; Ashizawa T; Yoshikawa S; Kiyohara Y; Yamaguchi K
Cancer Immunol Immunother; 2012 Dec; 61(12):2311-9. PubMed ID: 22707303
[TBL] [Abstract][Full Text] [Related]
20. Identification of erythropoietin receptor-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from HLA-A24(+) patients with renal cell carcinoma.
Minami T; Minami T; Shimizu N; Yamamoto Y; De Velasco M; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
Int Immunopharmacol; 2014 May; 20(1):59-65. PubMed ID: 24583149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
